To investigate preimplant risk factors associated with early right ventricular assist device (RVAD) use in patients undergoing continuous-flow left ventricular assist device (LVAD) surgery.
L
eft ventricular assist devices (LVADs) are increasingly used to treat refractory heart failure (HF) not only as a bridge to transplant but also as destination therapy. 1 The development of severe right HF (RHF) after LVAD surgery is a serious complication associated with increased morbidity and mortality. 2 Patients with postoperative RHF experience greater debilitation, delayed restoration of end-organ function, prolonged intensive care unit and hospital length of stay, and decreased survival. [2] [3] [4] [5] Therapeutic interventions for severe RHF after LVAD implantation are limited and include inotropic drugs or biventricular mechanical circulatory support (MCS). Planned temporary right ventricle (RV) support is feasible and has been demonstrated to improve outcomes compared with rescue therapy. 4, 5 Improved discrimination on risk of RHF would better inform clinical decision making for patients being considered for LVAD therapy. Currently, there is no consensus on how to best define a target population for isolated left ventricular support. Several RHF prediction rules have been developed previously. 2, [6] [7] [8] [9] [10] However, available risk scores have been typically derived from single-center cohorts, used variable definitions of RHF, identified inconsistent predictors, 11, 12 and have demonstrated modest predictive value when validated in independent cohorts. 12 The goal of the this study was to further explore preimplant characteristics associated with RV assist device (RVAD) use in patients undergoing continuous-flow (CF)-LVAD surgery using data from the multicenter interagency registry for mechanically assisted circulatory support (INTERMACS).
METHODS Patient Population and Characteristics
The INTERMACS is a prospective registry of approved durable MCS devices implanted in the North America (http://www. INTERMACS.org). The INTERMACS protocol was approved by the National Institutes of Health, the Institutional Review Board at the Data Coordinating Center at the University of Alabama at Birmingham, and each of the institutional review boards of the 144 participating hospitals. The study cohort includes patients ≥19 years of age who received a primary, intracorporeal CF-LVAD between June 2006 and March 2014.
Baseline epidemiological, biochemical, echocardiographic, and hemodynamic characteristics were obtained for all patients. LVAD type (axial versus centrifugal flow) was not available in the data set for comparison. Concomitant surgical procedures performed during the LVAD implant were included because they typically represent planned interventions and are potentially modifiable risk factors. Baseline oral medications were not included as candidate variables because both warfarin and international normalized ratios were selected in an early model. A previously defined model of RHF was examined. 2 From this model, a HeartMate II RV risk score was created: right atrial pressure (RAP)/pulmonary capillary wedge pressure >0.63 to 2 points; blood urea nitrogen level >39 mg/dL to 2 points; preoperative mechanical ventilation to 6 points. 13 This was evaluated as a dichotomous variable with a score >2 points (high risk) or ≤2 points (low risk). 14 The primary outcome was implantation of an RVAD within 14 days of the index LVAD implant. Coding within the INTERMACS data set did not allow further discrimination of RVAD devices as concomitant versus delayed or temporary versus permanent. Many early deaths after LVAD are attributable to severe RHF, so we performed a separate analysis to assess the model's ability to discriminate the risk of a composite end point of death or RVAD within 2 weeks. Odds ratios for the composite end-point model were re-estimated, and the changes in β-coefficients between the models were compared.
Statistical Analysis

Risk Model
Categorical variables are expressed as frequencies and percentages. Continuous variables are expressed as means if normally distributed or as medians if skewed. Differences between groups on categorical variables were compared using the χ 2 test, and differences between groups on continuous
WHAT IS NEW?
• Of 9976 patients undergoing continuous-flow left ventricular assist device surgery in the Interagency Registry for Mechanically Assisted Circulatory Support, ≈4% required a right ventricular assist device within 2 weeks of implantation.
• An additional 2% of patients experienced early death, many of which were likely secondary to severe right heart failure.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Preoperative right ventricular assessment should incorporate data from the general clinical assessment, blood work, cardiac imaging, and hemodynamic evaluation. Abnormal trends across multiple parameters best highlight the high-risk patient.
• Global markers of illness severity including evidence of end-organ dysfunction and the preoperative need for extracorporeal membrane oxygenation or dialysis are associated with increased right ventricular assist device use. Hemodynamic profiles of right heart failure include elevated right atrial pressure, narrow pulmonary artery pulse pressure, and reduced cardiac output, whereas echocardiographic profiles include severe tricuspid regurgitation and a less-dilated left ventricle.
• Intraoperative events can contribute to the risk of postoperative right heart failure. Concomitant cardiac surgical procedures during left ventricular assist device implantation are associated with right ventricular assist device use and require careful consideration during surgical planning.
variables were compared with the Student t test or nonparametric Wilcoxon rank-sum test as appropriate.
To identify risk factors for RVAD implantation, univariate logistic regression models were generated from all candidate variables. Variables missing >50% of data were excluded. For variables with <50% missing data, 10 imputed datasets were created using SAS 9.4 PROC MI procedure using the Markov Chain Monte Carlo method. All variables screened initially for inclusion in the model building process were used for the imputation models. Extreme values at the tails of the distribution for each variable were truncated at the 1st and 99th percentiles. Values beyond the 1st and 99th percentiles were replaced with values of the 1st and 99th percentiles, respectively. Derived variables were calculated using the imputed data set. To begin the model building process, stepwise forward logistic regression was performed using a threshold of P<0.05 to enter and stay in the model. Given that 10 copies of the data set were generated, each subject was assigned a weight of 1/10. Variables from the final regression model were run in each of the 10 copies of the data set, and the results were pooled using the SAS procedure PROC MIANALYZE to generate corrected P values and parameter estimates.
Nonadjusted associations of continuous variables with outcomes were assessed for linear fit using restricted cubic splines. When the assumption of a linear relationship between a continuous variable and log odds of the outcome violated, variables were truncated to an inflection point occurring at a change in slope and loss of linearity beyond an extreme value ( Figure I in the Data Supplement).
Several candidate variables correlated with each other. The choice of which variable to include in the model was made based both on clinical insight and statistical measures. When clinically there was no preference of which of 2 strongly correlated variables to include in the model, we allowed the one with the strongest statistical association to be included. All model refinements based on both clinical insight and statistical significance were run on the 10 imputed datasets with pooled parameters estimated with PROC MIANALYZE account for both within and between data set variability. Parameter estimates from the final model were used to generate fitted or predicted values of risk RVAD for each subject in the 10 copies of the imputed data. These fitted values were first used to produce an overall receiver operating characteristic curve area across all copies of the data. Patients were then grouped based on predicted risk of RVAD from the final model (<1%; 1≥risk<5%, 5≥risk<10%; and ≥10%), and baseline characteristics were compared across these risk strata.
Survival
Survival analyses were performed using the Kaplan-Meier method, with censoring for heart transplantation or LVAD explant for cardiac recovery. The log-rank test was used to compare survival between patients with and without RVAD. Cox proportional hazard modeling was performed on the imputed data set. The model was run for each of the 10 datasets, and the estimates were pooled to determine the adjusted hazard ratios and 95% confidence intervals. Adjustment variables in the Cox proportional hazards survival model included those from the final RVAD model in addition to age, sex, serum sodium, and blood urea nitrogen. A global test of proportional hazards was performed using the global correlation test on weighted Schoenfeld residuals. All statistical analyses were performed with SAS, version 9.4 (SAS institute, Inc, Cary, NC).
RESULTS
The final analysis cohort consisted of 9976 patients undergoing primary CF-LVAD, and 386 (3.9%) received an RVAD within 14 days of LVAD implantation (Figure 1) . Patients requiring an RVAD were generally more ill at the time of LVAD surgery as represented by a greater proportion with INTERMACS profiles 1 or 2, and New York Heart Association class IV functional status (Table 1) . Patients requiring RVAD were less likely to be receiving neurohormonal antagonist therapy and had a worse biochemical profile. RVAD recipients had more severe hemodynamic derangements including higher RAP, lower pulmonary artery pulse pressure (PAPP), and lower stroke volume. Patients requiring RVAD placement also had substantially higher preimplant rate of temporary mechanical support including extracorporeal membrane oxygenation and intra-aortic balloon pump, mechanical ventilation, and renal replacement therapy. The HeartMate II RV risk score was ≥2 in 77% of patients requiring RVAD versus 53% of patients receiving an LVAD alone (P<0.0001).
Risk Factors for RVAD
The unadjusted odds ratios for RVAD use associated with baseline characteristics are available in Table I Patient baseline characteristics according to strata of predicted risk for RVAD from the multivariable model are summarized in Table 3 . The actual incidence of RVAD use was 16.2% in the highest risk decile compared with the predicted incidence of 15.8% ( Figure II in the Data Supplement). Among patients with an estimated probability of RVAD use ≥10%, 73% were INTERMACS profile 1, 30% were on extracorporeal membrane oxygenation, 18% were on renal replacement therapies, and 72% had a concomitant procedure (Table 3) . Median serum creatinine for this high-risk group was 1.5 mg/ dL. Median left ventricular end diastolic diameter was 6.2 mm in those with a ≥10% risk compared with 7.2 mm in patients with risk <1%. Severe tricuspid regurgitation was more common in the highest versus lowest risk strata (27% versus 3%). Patients with an estimated risk ≥10% had a median RAP of 18.6 mm Hg and PAPP of 17.1 mm Hg, whereas the group with an estimated risk <1% had a median RAP of 8 mm Hg and PAPP of 28 mm Hg. Each 1-mm Hg increase in RAP was associated with a 5% increase in the risk of RVAD, whereas each 1-mm Hg increase in PAPP was associated with a 4% decrease in risk (Table 2) . After adjustment for other risk factors, INTERMACS profile 1 was associated with 2.79× greater risk than profiles 3 to 7 ( Table 2) . The HeartMate II RV risk score was not independently associated with RVAD use.
Risk of Early RVAD or Death
There were 222 early deaths and 608 composite events including death or RVAD. The C statistic of the multivariable RVAD model for the composite end-point model was 0.73. Actual and predicted incidence of death/ RVAD increased proportionally across risk deciles, demonstrating that the model accurately discriminates risk of the composite event. Larger differences were found between actual versus predicted events, signifying that the composite model is less accurately calibrated as would be anticipated given that it was derived to predict risk of RVAD alone. Fourteen of the 16 variables from the RVAD model retained significance in the composite model, and covariate β coefficients remained stable in the new model with <25% change in value for all but 5 variables. Collectively, these data suggest that predictors of RVAD use have a similar association with the composite end point of death or RVAD.
Early RVAD and Survival
Patients who received an early RVAD had decreased survival compared with those who received an isolated LVAD (log-rank for linear trend P≤0.0001; Figure 3 ). Thirty-day survival from the time of LVAD implantation was 73.5% versus 96.1%. The unadjusted hazard ratio for death associated with early RVAD was 3.12 (95% ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; BNP, brain natriuretic peptide; bpm, beats per minute; BUN, blood urea nitrogen; CABG, coronary artery bypass graft surgery; ECMO, extracorporeal membrane oxygenation; HMII, HeartMateII; IABP, intra-aortic balloon pump; INR, international normalized ratio; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVAD, left ventricular assist device; LVEDD, left ventricular end diastolic diameter; MAP, mean arterial pressure; MI, myocardial infarction; PADP, pulmonary artery diastolic pressure; PAPI, pulmonary artery pulsatility index; PAPP, pulmonary artery pulse pressure; PASP, pulmonary artery systolic pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RV, right ventricle; RVAD, right ventricular assist device; RVSWI, right ventricular stroke work index; TPG, transpulmonary gradient; TVR, tricuspid valve repair; UF, ultrafiltration; WBC, white blood cell; and WU, Wood units. 
DISCUSSION
The INTERMACS registry provides a rich resource for evaluating outcomes after LVAD surgery, and this study represents the largest analysis of RVAD use among a contemporary cohort of patients undergoing CF-LVAD surgery. A prior multicenter study of RHF after LVAD was conducted in a bridge to transplant population using a single device and had only 30 RVAD events 2 compared with the 386 events available in this analysis. Our findings confirm many of the risk factors for early *Concomitant TV repair, which has a nonsignificant association with early RVAD, is included in the model as part of a three level variable with no concomitant procedure as the referent group. †Referent group: profiles 3 to 7.
RHF after LVAD previously identified in smaller studies and provide a foundation for more precise estimation of risk on the need for RVAD support in LVAD candidates. Because many early deaths after LVAD implantation are likely attributable to severe RHF, we also demonstrated that the model discriminated risk of the composite end point of RVAD or death. Outcomes with isolated LVADs are consistently better than with total artificial heart or biventricular MCS. 1 When feasible, LVAD support alone is, therefore, the preferred MCS strategy. Furthermore, in some observational studies, delayed RVAD is associated with worse outcomes compared with early RVAD. 4, 5 Thus, having greater accuracy to predict the need for RV mechanical support is of paramount clinical importance. Currently available models to predict RHF after LVAD had demonstrated at best modest performance in validation cohorts, and these studies have included small number of RVAD recipients. This study provides an opportunity to examine risk factors specifically for RVAD use with higher fidelity around the risk associated with different clinical factors to help aid in clinical decision making.
There was clear evidence from multiple domains that patients requiring early RVAD support were more ill at the time of LVAD implant than those who did not require an RVAD. INTERMACS patient profiles were found to be independently associated with RVAD use. Profiles 1 (crash and burn) and 2 (sliding on inotropes) were associated with 2 to 3× the risk of RVAD compared with profiles 4 to 7. However, only 10% of profile 1 and 4% of profile 2 patients required RVAD support, highlighting the need to incorporate other risk factors into LVAD patient selection.
Hemodynamic assessment has a central role in understanding RV performance, and several prior studies have identified different hemodynamic metrics as risk factors for RHF after LVAD. 2, [6] [7] [8] Although the relationship between cardiac and vascular function on arterial pulse pressure is complex, in advanced heart failure with reduced ejection fraction, a narrow arterial pulse pressure is an established marker of poor hemodynamic status and a predictor of adverse outcomes. [15] [16] [17] [18] Extrapolating correlations from the systemic to the pulmonary circulation are limited by physiological differences in the anatomy and function of these distinct chambers and vascular beds. Nevertheless, narrow PAPP seems to be a correlate of impaired RV function and was independently associated with RVAD use. Similar to other published studies, elevated RAP was a strong risk factor for RVAD implant. 6, 9, 10, 19 Two prior studies identified the pulmonary artery pulsatility index (PAPP/RAP) as a risk factor for RVAD. 19, 20 Although the component variables of the pulmonary artery pulsatility index were predictors in the INTERMACS model, the index itself did not add incremental value to risk prediction. Similarly, RAP/pulmonary capillary wedge pressure ratio 2 had a significant univariate association with RVAD use but in contrast to RAP alone, was not an independent predictor. However, given that some of these hemodynamic variables are highly correlated, it should be noted that alternative models with similar performance could likely be derived from this same data set using these alternative covariates.
History of coronary artery bypass graft surgery or valve surgery was associated with increased risk of RVAD because it is likely that past cardiac surgery increases the risk of RV injury, prolonged cardiopulmonary bypass time, and perioperative bleeding. Excessive transfusion can precipitate RHF by causing RV distension and increased pulmonary vascular resistance. 21, 22 Concomitant surgery at the time of LVAD implant was also associated with RVAD use, which may be related to prolonged cardiopulmonary bypass time, the need for cardioplegia, or myocardial ischemia, which are detrimental to RV function.
As reported elsewhere, 23, 24 severe preimplant tricuspid regurgitation was associated with RVAD use. Concomitant tricuspid valve repair, however, was not associated with RVAD risk in the INTERMACS registry. This finding is similar to those from the Society for Thoracic Surgeons 25 and the ADVANCE trial (Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure) datasets. 23 Among patients with severe tricuspid regurgitation undergoing implantation of a centrifugal-flow LVAD, those who received concomitant tricuspid valve repair were less likely to develop late RHF. 23 Whether tricuspid regurgitation should be corrected at the time of LVAD implantation remains uncertain, but the INTERMACS data provide reassurance that tricuspid valve repair does not seem to result in an increased need for RVAD support.
The association between lower left ventricular end diastolic diameter and RVAD use has been reported. 26, 27 Patients with refractory HF and a nondilated left ventricle may be experiencing either a restrictive cardiomyopathy with RV involvement or a predominantly a right-sided HF syndrome, both of which are less likely to improve with left-sided support alone. Patients with a nondilated left ventricle may also be more prone to the impact of the LVAD on mechanical ventricular interdependence. 22 To improve clinician usability, most of the published risk scores for RHF have dichotomized continuous variables at optimal cut points to define patients at high risk. This approach may fail to capture continuum of risk associated with these variables by imposing a somewhat arbitrary binary threshold. Dichotomization of variables can create false reassurance when a predictor is below a given threshold. We present the INTERMACS RVAD model in its entirety with the associated odds ratios for each predictor to allow clinicians to appraise the magnitude of risk for RVAD use accompanied by different patient characteristics. This approach also avoids assigning excessive weight to a single factor because complete understanding of RHF integrates information across multiple RV functional domains including echocardiographic, biochemical, and hemodynamic profiles. An integrated, multimodality approach to RV assessment is important to guide decision making before LVAD implantation.
Establishing prohibitive thresholds of RVAD risk is challenging. These thresholds would likely vary by patient, dependent on factors including age and implant strategy. It may be reasonable to assume a higher level of risk if transplantation is possible, allowing RVAD support to be temporary should it be necessary. A long-term RVAD would be suboptimal in a CF-LVAD recipient implanted as destination therapy, in whom greater emphasis is placed on nonsurvival outcomes associated with longterm support including quality of life and functionality. DT LVAD surgery is increasingly viewed as a semielective procedure to be avoided in patients with critical cardiogenic shock with end-organ dysfunction, requiring extracorporeal membrane oxygenation or renal replacement therapies, all independent predictors of RVAD use. National trends have demonstrated a decline in LVAD implantation among profile 1 patients, consistent with avoiding LVAD use in these higher risk cohorts. 
Limitations
Limitations of this study include its retrospective nature, as well as those associated with registry data. There was substantial missing data in the registry. Right heart catheterization variables were missing for >20% of observations, which was accounted for with multiple imputation-a standard statistical technique. Omission of these observations may introduce bias given nondifferential patterns of missingness. Despite truncating extreme outliers, a few implausible data points remained. The absolute number of these outliers was small and unlikely to impact study findings.
A major factor limiting the use of RHF prediction includes the challenges associated with RV imaging and inability to incorporate quantitative RV functional assessment into risk models. 28 Indeed, echocardiographic assessment of qualitative RV function was missing in >50% of subjects and was excluded from analyses. Furthermore, the physiology of postoperative RHF is complex with several potential contributing pathophysiologic pathways. Intraoperative variables that predispose to RHF, including RV ischemia, changes in RV volume because of transfusion, increases in pulmonary vascular resistance associated with cardiopulmonary bypass, acidosis, or hypoxia, and the impact of LVAD output on RV loading, geometry, and function, are not available for comparison. 22 Furthermore, the low prevalence of RVAD use limits the positive predictive value of prediction models. Finally, it remains unclear whether the variables identified in this analysis are relevant to other forms of RHF after LVAD surgery including the need for prolonged inotropic support.
CONCLUSIONS
This study is the largest multicenter experience exploring preoperative characteristics associated with RVAD use after CF-LVAD implant. Correlates of increased clinical acuity, including markers of end-organ dysfunction and profiles of hemodynamic instability, are associated with RVAD use. Preoperative prediction remains challenging given the complex nature of postoperative RHF and the low prevalence of RVAD use. The risk factors identified in our final model should supplement the clinical judgment of a multidisciplinary team during patient selection and preoperative planning for LVAD surgery.
SOURCES OF FUNDING
This project was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, award number UL1TR001064. Data collection for this work was funded in whole or in part with Federal Funds from the National Heart, Lung and Blood Institute, National Institutes of Health, Department of Heath and Human Services, under Contract No. HHSN268201100025C. The content was generated through an INTERMACS collaboration. We would like to thank the INTERMACS investigators, coordinators, and participating institutions for the data they have provided for this registry.
DISCLOSURES
Dr Birati has received fellowship and research support from Medtronic. Dr Kiernan has received consulting and speaking honoraria from Medtronic and sponsored travel from Abbott.
